Professor Rostami is the Senior Vice President of Research & Development and Chief Scientific Officer at Certara. His mission is to ensure that the latest scientific advances in the field of biosimulation are incorporated into all of the drug development efforts by various pharmaceutical companies. He joined Certara in 2012 as a co-founder of Simcyp Limited, a University of Sheffield spin-off which was acquired by Certara.
Amin is also a Professor of Systems Pharmacology and the Director of the Centre for Applied Pharmacokinetic Research (CAPKR) at the University of Manchester. He has an active program of training Ph.D. students involving proteomics, physiologically-based pharmacokinetics and pharmacodynamics, and precision dosing within CAPKR, and numerous graduates from his team are currently active in the pharmaceutical industry or academic research.
Professor Rostami was the first full Professor appointed with the title of Systems Pharmacology in 2007 whilst working at the University of Sheffield, He has authored/co-authored more than 290 highly cited articles (>17,500 citations, H-Factor >72). In 2017, he was listed by ISI as one of the world’s most highly cited researchers under ‘Pharmacology & Toxicology,’ and he is on the 2020 top 0.06% of the highest cited researchers list by Elsevier for the field of Pharmacology/Pharmacy. He was a founding editor of Pharmacometrics and System Pharmacology and has served on the Editorial Boards of several other journals. Professor Rostami is renowned for his contribution to translational modelling (e.g. PBPK) and has been an invited speaker at over 200 international meetings, in addition to leading numerous workshops in the area of IVIVE-PBPK linked models.